The launch of generic liraglutide (Teva, August 2025) and anticipated oral GLP-1 options (oral Wegovy approved December 2025, orforglipron pending) offer lower-cost alternatives that may simplify pharmacy benefit management
Sermorelin is the optimal choice for research centered on long-term hormonal homeostasis, sleep quality, anti-aging mechanisms, and sustainable endocrine support
However, these reports must be carefully considered, and recent analyses confirmed that, when prescribed according to the recommended dosage, T replacement therapy in hypogonadal patients improves angina symptoms in subjects with ischemic heart disease and exercise ability in patients with heart failure [91]
Glucagon-receptor agonism increases energy expenditure and hepatic fat mobilization, which is part of why retatrutide is so effective at reducing fat and liver fat